Clinical study of anticoagulant therapy on hypercoagulable state and anti-tumor metastasis in advanced gastric cancer

doi:10.12092/j.issn.1009-2501.2019.04.011

Abstract

Abstract:

AIM: To analyze the relationship between coagulation parameters and clinic pathological features of gastric cancer patients, and observe the effect of anticoagulant therapy on hypercoagulable state, tumor metastasis/recurrence, survival status and safety evaluation of gastric cancer. METHODS: 140 patients with gastric cancer were selected to analyze the relationship between coagulation parameters and clinic pathological features. 172 patients with stage III gastric cancer were enrolled, including 116 patients in the treatment group (prophylactic anticoagulant therapy combined with postoperative adjuvant chemotherapy) and 56 patients in the control group (postoperative adjuvant chemotherapy). The anticoagulant therapy was observed on hypercoagulable state and tumor metastasis/recurrence, impact of survival and safety assessment. RESULTS:D-dimer of lymph node metastasis N1-3 group was higher than N0 group (P<0.05), stage III and IV were higher than stage I and II of FIB, D-dimer, and APTT value was decreased (P<0.05). Before and after anticoagulant therapy in the treatment group, PT and APTT were prolonged, D-dimer and FIB were decreased (P<0.05). The rate of lymph node and liver metastasis in the treatment group was lower than that in the control group in 12, 24 and 36 months (P<0.05). The 2-year and 3-year survival rates of the treatment group were higher than those of the control group (P<0.05), and the median survival and disease-free survival were longer than the control group. There was no significant difference in the incidence of gingival bleeding, thrombocytopenia, and ecchymosis of the skin between the two groups (P>0.05). CONCLUSION:The factors influencing the hypercoagulable state of gastric cancer are lymph node metastasis and TNM staging. Anticoagulant therapy can improve hypercoagulability, reduce the rate of lymph node and liver metastasis, and prolong survival without increasing the incidence of adverse reactions.

Key words: anticoagulant therapy, gastric cancer, hypercoagulable state, metastasis, survival analysis

CLC Number:

R735.2

ZHANG Tengyue, YANG Guangshan, MA Kelong, FAN Pingsheng. Clinical study of anticoagulant therapy on hypercoagulable state and anti-tumor metastasis in advanced gastric cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 433-439.

References

［1］Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer ［J］. Tumour Biol, 2017, 39(7): 1010428317714626.
［2］Remiker AS,Palumbo JS.Mechanisms coupling thrombin to metastasis and tumorigenesis［J］.Thromb Res,2018,164 Suppl 1:S29-S33.
［3］Repetto O, De Re V. Coagulation and fibrinolysis in gastric cancer ［J］. Ann N Y Acad Sci, 2017, 1404(1): 27-48.
［4］Kwon OK, Kim SW, Chae HD, et al. Validation of the 7th AJCC/UICC staging system for gastric cancer and a proposal for a new TNM system based on a prognostic score: a retrospective multicenter study ［J］. Ann Surg Treat Res, 2016, 91(6): 295-302.
［5］Sun RQ, Yang HF. The application of disseminated intravascular coagulation score in sepsis ［J］. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2009, 21(8): 478-480.
［6］Refaai MA, Riley P, Mardovina T, et al. The clinical significance of fibrin monomers［J］. Thromb Haemost, 2018, 118(11): 1856-1866.
［7］Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon ［J］. Arch Intern Med, 2004, 164(2): 190-194.
［8］Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test ［J］? Vasc Med, 2018, 23(4): 388-399.
［9］郑青秀, 徐小小, 刘刚, 等. 补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响［J］.中国临床药理学与治疗学, 2018, 23(6): 694-699.
［10］Martín Guerra JM, Asenjo MM, Dueas Gutiérrez CJ, et al. Synchronous cardiopulmonary consequences of the hypercoagulable state associated with cancer ［J］. Arch Bronconeumol, 2018, pii: S0300-2896(18)30328-4.
［11］De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms ［J］. Crit Rev Oncol Hematol, 2004, 50(3): 187-196.
［12］Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer ［J］. J Clin Oncol, 2009, 27(29): 4874-4880.
［13］王洛波, 王兵,丁语, 等. 利伐沙班和华法林治疗下肢深静脉血栓形成的疗效比较［J］. 医药导报, 2016, 35(10): 1089-1091.
［14］Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer［J］. J Clin Oncol, 2007, 25(34): 5490-5505.
［15］Remiker AS, Palumbo JS. Mechanisms coupling thrombin to metastasis and tumorigenesis［J］. Thromb Res, 2018, 164 Suppl 1: S29-S33.
［16］Smorenburg SM, Van Noorden CJ. The compex effects of heparins on cancer progression and metastasis in experimental studies ［J］. Pharmacol Rev, 2001, 53(1): 932105
［17］Kragh M, Binderup L, Vig Hjarnaa PJ, et al. Non-anti-coagulant heparin Inhibits metastasis but not primary tumor growth ［J］. Oncol Rep, 2005, 14 (1) : 992104.
［18］Yoshitomi Y, Nakanishi H, Kusano Y, et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemicallymodified heparin with reduced anticoagulant activity ［J］. Cancer Lett, 2004, 207(2): 1652174
［19］Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)［J］. J Clin Oncol, 2004, 22(10): 1944-1948.
［20］椰慧楠, 王哲, 汪忠淼. 低分子肝素对恶性肿瘤患者血液高凝状态以及生存率的影响［J］. 疑难病杂志, 2016, 15(3): 273-275,279.

[1]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[2]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[3]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[4]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[5]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[6]	LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao. Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
[7]	JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi. AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
[8]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[9]	SONG Dandan, CHEN Xueyuan, CHEN Ruiqi, LI Hanqiao, WU Tian. Research status of long non-coding RNA MALAT1 in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 49-57.
[10]	WU Yi, ZHU Akao, SHAN Yuqiang, YING Rongchao, JIN Huicheng. Resveratrol regulates miR-409-3p/FKBP14 to inhibit the malignant biological processes of gastric cancer BGC823 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 968-975.
[11]	TIAN Dahao, LU Linming, ZHI Hui, ZHOU Jue, WANG Xiaoqing, JIANG Yuhua. AHVAC-I inhibits the proliferation in human primary gastric cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 505-511.
[12]	SHEN Cheng, YANG Nianzhao, WANG Minghai, WU Lisheng, ZHU Zhiqiang. Inhibiting RNA methylase NSUN2 reduce the invasion and migration of gastric cancer cell [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 380-386.
[13]	LIU Yujia, LI Li, HU Xiaoping, ZHONG Like, LI Jingjing, HUANG Ping, ZHANG Yiwen. A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 852-859.
[14]	ZHOU Qingying, XU Naifen, ZHENG Dingqin, PAN Qizhuang, ZHANG Zhigang, WANG Shuo. Fluorouracil regulates VHL/HIF signaling pathway and inhibits proliferation, invasion and metastasis of renal carcinoma cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 872-879.
[15]	TENG Xiaojing, DONG Xueyan, WANG Zhiyi, YU Daojun, WANG Xianjun. Experimental study of Fuzheng Kangfu mixture combined with cisplatin on apoptosis of the gastric cancer cell SGC7901 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 744-749.